Magdalena Skubal

Magdalena Skubal

Auto-generated profile, based on publicly available information

Magdalena Skubal

Memorial Sloan Kettering Cancer Center

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2022 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
EPEdwin C. Pratt
Edwin C. Pratt
MSMagdalena Skubal
Magdalena Skubal
BLBenedict Mc Larney
Benedict Mc Larney
PCPamela Causa-Andrieu
Pamela Causa-Andrieu
SDSudeep Das
Sudeep Das
JGJan Grimm
Jan Grimm

21 January 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
Martin K. BakhtMartin K. Bakht
Martin K. Bakht
JHJohn Hayward
John Hayward
FSFarsheed Shahbazi-Raz
Farsheed Shahbazi-Raz
MSMagdalena Skubal
Magdalena Skubal
RTRyo Tamura
Ryo Tamura
JTJohn Trant
John Trant
Significance: Glutamate-ureido-lysine (GUL) probes are specific for prostate-specific membrane antigen (PSMA), overexpressed by most prostate cancers. This antigen can be lost as the cancer progresses. Recent reports have indicated that GUL probes can still identify these PSMA-negative tumors, indicating that the expression of alternative PSMA-like proteins may change during disease progression. In this study we identified two such candidate protein targets, NAALADaseL and mGluR8, by using a combined computational chemistry, data mining, molecular biology, radiochemistry, and synthetic chemistry approach. This work consequently prepares the groundwork for developing specific probes that can identify this progression, indicates directions for neuroendocrine prostate cancer research, and highlights the utility of a multidisciplinary approach for the rapid identification of unidentified proteins interacting with diagnostic probes.

8 December 2014 in Hippocampus
Verified
Journal Article
Closed access
PDF file
STSada Lakshmi Turimella
Sada Lakshmi Turimella
PBPeter Bedner
Peter Bedner
MSMagdalena Skubal
Magdalena Skubal
VVVamshidhar Reddy Vangoor
Vamshidhar Reddy Vangoor
LKLech Kaczmarczyk
Lech Kaczmarczyk
MTMartin Theis
Martin Theis

1 August 2021 in Cancer Letters
Verified
Journal Article
Closed access
HKHarald Krenzlin
Harald Krenzlin
MZMykola Zdioruk
Mykola Zdioruk
MNMichal O. Nowicki
Michal O. Nowicki
TFTomer Finkelberg
Tomer Finkelberg
NKNaureen Keric
Naureen Keric
SLSean Lawler
Sean Lawler

26 February 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
CMCamila Maria Longo Machado
Camila Maria Longo Machado
MSMagdalena Skubal
Magdalena Skubal
KHKatja Haedicke
Katja Haedicke
FPFabio Pittella-Silva
Fabio Pittella-Silva
ESEvan Paul Stater
Evan Paul Stater
JGJan Grimm
Jan Grimm
Extracellular vesicles (EV) are comprised of vesicles budding from cell membranes and smaller intracellular vesicles shed by cells. EV play a role in remodeling the tumor microenvironment (TME) and support tumor progression. Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein with a carboxypeptidase function, frequently associated with poor clinical prognosis in prostate cancer (PCa). We previously identified an oncogenic PSMA signaling function in prostate cancer. Others demonstrated that EV isolated from the plasma of patients with high-grade PCa carry PSMA, but so far no pathophysiological effect has been associated with PSMA-bearing EV. Here we demonstrate that EV from PCa cells are able to transfer PSMA and its functionality to cells in the TME. The consequence of that EV-mediated PSMA transfer is an acute to long-term increased secretion of vascular endothelial growth factor-A (VEGF-A), angiogenin, pro-angiogenic and pro-lymphangiogenic mediators and increased 4E binding protein 1 (4EBP-1) phosphorylation in tumors. We compare EV from PCa cells with or without PSMA expression to address the role of PSMA-bearing EV in promoting pro-tumoral changes in the TME using classical molecular biology and novel molecular imaging approaches.

8 August 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
MSMagdalena Skubal
Magdalena Skubal
BLBenedict Edward Mc Larney
Benedict Edward Mc Larney
NPNgan Bao Phung
Ngan Bao Phung
JDJuan Carlos Desmaras
Juan Carlos Desmaras
ADAbdul Vehab Dozic
Abdul Vehab Dozic
JGJan Grimm
Jan Grimm
The cascade of events leading to tumor formation includes induction of a tumor supporting neovasculature as a primary hallmark of cancer. Developing vasculature is difficult to evaluate in vivo but can be captured using microfluidic chip technology and patient derived cells. Herein, we established an on chip approach to investigate the mechanisms promoting tumor vascularization and vascular targeted therapies via co-culture of metastatic renal cell carcinoma spheroids and endothelial cells in a 3D environment. Our model permitted real-time, high-resolution observation and assessment of tumor-induced angiogenesis, where endothelial cells sprout towards the tumor and mimic a vascular network. Bevacizumab, an angiogenic inhibitor, disrupted interactions between vessels and tumors, destroying the vascular network. The on chip approach enabled assessment of endothelial cell biology, vessel’s functionality, drug delivery, and molecular expression of PSMA. Finally, observations in the vascularized tumor on chip permitted direct and conclusive quantification of this therapy in weeks as opposed to months in a comparable animal model. Teaser: Vascularized tumor on microfluidic chip provides opportunity to study targeted therapies and improves preclinical drug discovery.